Objective: We analyzed the nomophobia concept to develop the "Fırat Nomophobia Scale" to determine the level of nomophobia in individuals aged 15-65 years.Design and Measures: A linguistically and psychometrically validated trial form consisting of 13 statements was applied to a sample of 678 individuals (69% women).
Results:The "Nomophobia Scale" that we developed consisted of a single dimension and eight items, explicating 55.9% of the variance concerning nomophobia.Conclusions: Our findings suggest that the Fırat Nomophobia Scale is an economical scale with a low number of items and high variance. In addition, it provides valid and reliable measurements.Practice Implications: The present study signifies the importance of research on nomophobia and determining the risk groups and protection strategies.
Aim
This study aimed to the smoking levels of the healthcare personnel (
n
= 761) in Turkey, the changes in their smoking levels, and their mental well‐being levels.
Design and Methods
Data were collected via social networks from various cities in Turkey using a personal information form, the Fagerstrom test for nicotine dependence, the Warwick–Edinburgh mental well‐being scale.
Findings
Their mean nicotine dependence score was 3.50 ± 2.57 and mental well‐being score was 25.01 ± 5.44. The frequency of smoking during the pandemic was increased in 22.4% of the participants and was the same as that before the pandemic in 57.4% of the smokers.
Practice Implications
It is an introductory study of the current situation for healthcare professionals and researchers. It suggests protecting mental well‐being and reducing smoking.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.